



MEDIA RELEASE

VivaZome Therapeutics presents three posters highlighting exosome purification, customisation and manufacturing at the annual ANZSEV national exosome conference

10 November 2023, Melbourne, Australia: VivaZome Therapeutics Pty Ltd (“VivaZome”) is presenting three posters at the 6th annual meeting of the Australian and New Zealand Society of Extracellular Vesicles (ANZSEV) being held this week in the Barossa Valley, South Australia. These posters highlight strategies and technologies for extracellular vesicle (EV) purification, customisation and manufacturing:

1. “From Laboratory to “Manufacturing Methods and Challenges in Exosome Purification” (Shambrook *et al*)
 - This poster outlines VivaZome’s current research-scale purification process for EVs and explores options for clinical-scale processing.
 - The authors conclude that the isolation process yields EVs that meet classical characterisation criteria, including the correct size range, shape and expression of EV-associated protein markers.
2. “Customisation Strategies and Loading of EVs to Treat Neurological Disease” (Johnston *et al*):
 - The second poster focuses on strategies for customising EVs including surface and luminal EV modifications and the associated advantages and considerations.
 - The authors emphasise the importance of confirming effective EV-modification and functionality.
3. “Establishing a Robust Exosome Manufacturing Process for Translational Studies” (Krishna *et al*):
 - The third poster outlines VivaZome’s roadmap for establishing manufacturing and analytical facilities that will support translational studies, addressing pre-clinical, clinical and regulatory requirements.
 - The authors emphasise the importance of maintaining EV integrity and functionality including the safety, pharmacokinetic and pharmacodynamic characteristics of the EV product as it is translated into the clinic.

These posters collectively demonstrate VivaZome’s commitment to advancing the field of EV therapeutics from research-scale processes to potential clinical applications, underscoring the company’s dedication to translating its research into practical and impactful solutions for neurological and other diseases.

Dr David Haylock, Chief Scientific Officer of VivaZome, said: “We are delighted to be presenting this work at the ANZSEV meeting as we strive to develop new customised EV-based approaches to develop impactful treatments for retinal disease and traumatic brain injury with our esteemed collaborators at Australian National University, The University of Queensland, Cytiva and SeerPharma. These posters highlight the strong progress we are making. Presenting at this excellent event provides an opportunity to showcase the company’s advancements, share insights with peers, and contribute to the broader discussion within the Scientific community.”

The ANZSEV Annual Meeting is the major Australasian scientific conference in the field of EVs. It brings together researchers and scientists from Australia and New Zealand along with international visitors and invited speakers. VivaZome is a silver sponsor of the conference.

For further information, contact:

Ms Xenia Sango, CEO, VivaZome Therapeutics Pty Ltd

xenia.sango@vivazome.com

Phone: +61 (0)406 180 812

About VivaZome:

VivaZome Therapeutics Pty Ltd is a privately-held Australian biotech company, with operational headquarters at the La Trobe University in Melbourne, Australia. VivaZome aims to develop and commercialise customised exosome-based therapies for debilitating and life-threatening disorders, with a focus on neurological disorders, retinal disease and ischaemic conditions. VivaZome is developing new technologies, intellectual property and manufacturing processes that apply generically to exosome therapies. These will underpin the Company's development of specific exosome products for its target indications. The VivaZome team has extensive expertise in the development and commercialisation of biological therapies, together with a wide network of expert contacts in the Australian and global biotech communities.

VivaZome acknowledges the support of the Department of Industry and Science through the CRC-P program, and the contribution of its CRC-P partners: Australian National University, the University of Queensland, La Trobe University, Cytiva and SeerPharma Pty Ltd.

For more information, please visit www.vivazome.com